Redeye maintains a positive view on Dynavox, which delivered another quarter of impressive growth, with 33% organic sales expansion and continued momentum across geographies and user groups. Despite heavy one-off investments, underlying profitability is strengthening as the business scales. We see the strong start to 2025 as clear evidence of Dynavox’s ability to combine high-quality growth with operational improvements, while the M&A adds further fuel to the growth story. While short-term USD/SEK depreciation will weigh on near-term top-line growth, margin impacts are expected to be limited. We have updated our estimates, factoring in the continued momentum that partially offsets FX effects.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/